3. Kapp N, Abitbol JL, MatheÌ H, Scherrer B, Guillard H, Gainer E, Ulmann A. Effect of body weight and BMI on the efficacy of levonorgestrel emergency contraception. Contraception.2015 Feb; 91(2).

4. Praditpan P, Hamouie A, Basaraba CN, Nandakumar R, Cremers S, Davis AR, et al. Pharmacokinetics of levonorgestrel and ulipristal acetate emergency contraception in women with normal and obese body mass index. Contraception. 2017.

5. Festin MP, Peregoudov A, Seuc A, Kiarie J, Temmerman M. Effect of BMI and body weight on pregnancy rates with LNG as emergency contraception: analysis of four WHO HRP studies. Contraception. 2017.

6. Piaggio G, Kapp N, von Hertzen H. Effect on pregnancy rates of the delay in the administration of levonorgestrel for emergency contraception: a combined analysis of four WHO trials. Contraception. 2011.

7. Creinin MD, Schlaff W, Archer DF, et al. Progesterone receptor modulator for emergency contraception: a randomized controlled trial. Obstetrics & Gynecology. 2006.

8. Piaggio G, von Hertzen H, Grimes DA, Van Look PF. Timing of emergency contraception with levonorgestrel or the Yuzpe regimen. Task Force on Postovulatory Methods of Fertility Regulation. The Lancet. 1999; 353(9154):721.

9. von Hertzen H, Piaggio G, Ding J, et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. The Lancet 2002;360(9348).

10. Festin MP, Bahamondes L, Nguyen et al. A prospective, open-label, single arm, multicentre study to evaluate efficacy, safety and acceptability of pericoital oral contraception using levonorgestrel 1.5 mg // Hum Reprod. 2016 Mar; 31(3):530-40. doi: 10.1093/humrep/dev341. Epub 2016 Jan 31.

11. Harper CC, Rocca CH, Darney PD. Tolerability of levonorgestrel emergency contraception in adolescents.// Am J Obstet Gynecol. 2004 Oct; 191(4):1158-63.

12. Raine TR, Ricciotti N, Sokoloff A. et al. An over-the-counter simulation study of a single-tablet emergency contraceptive in young females.// Obstet Gynecol. 2012 Apr; 119(4):772-9.

13. ACOG. Practice Bulletin No. 152: Emergency Contraception.// Obstet Gynecol. 2015 Sep;126(3):e1-11.

14. Adamson G.D. et al. Endometriosis fertility index: the new, validated endometriosis staging system // Fertil. Steril. 2010. Vol. 94 (5). P. 1609–1615.

15. Combined Hormonal Contraception January 2019 (Amended July 2019). Faculty of Sexual & Reproductive Healthcare. January 2019.

16. Trussell J. Contraceptive efficacy. In: Hatcher RA, Trussell J, Nelson AL, Cates W, Kowal D, Policar M, editors. Contraceptive technology: twentieth revised edition. NewYork (NY): Ardent Media; 2011.

17. Медицинские критерии приемлемости для использования методов контрацепции / ВОЗ. 5-е изд. 2015.

18. Smith JD, Oakley D. Why do women miss oral contraceptive pills? An analysis of women’s self-described reasons for missed pills.// J Midwifery Womens Health. 2005 Sep-Oct;50(5):380-5.

Глава 3. Гормональная контрацепция

1. Медицинские критерии приемлемости для использования методов контрацепции / ВОЗ. 5-е изд. 2015.

2. Национальные медицинские критерии приемлемости методов контрацепции. М., 2012.

3. Christin-Maitre S. History of oral contraceptive drugs and their use worldwide. Best Pract Res Clin Endocrinol Metab. 2013;27(1):3-12. doi:10.1016/j.beem.2012.11.004.

4. Regidor PA. Clinical relevance in present day hormonal contraception. Horm Mol Biol Clin Investig.2018;37(1):/j/hmbci.2019.37.issue-1/hmbci-2018-0030/hmbci-2018-0030.xml. Published 2018 Oct 26. doi:10.1515/hmbci-2018-0030.

5. Wasiak R, Filonenko A, Vanness DJ, et al. Impact of estradiol valerate/dienogest on work productivity and activities of daily living in women with heavy menstrual bleeding. J Womens Health (Larchmt). 2013;22(4):378–384. doi:10.1089/jwh.2012.3633.

6. Regidor PA, Schindler AE. Antiandrogenic and antimineralocorticoid health benefits of COC containing newer progestogens: dienogest and drospirenone. Oncotarget. 2017;8(47):83334-83342. Published 2017 Aug 3. doi:10.18632/oncotarget.19833.

7. Управление менструальным циклом: новые возможности. Инновации в контрацепции – гибкий пролонгированный режим и цифровые технологии дозирования: информационный бюллетень / М. Б. Хамошина, М. Г. Лебедева, Н. Л. Артикова, Т. А. Добрецова; под ред. В. Е. Радзинского – М.: Редакция журнала StatusPraesens, 2016. – 24 с.

8. Сперофф Леон, Дарни Филип Д. Клиническое руководство по контрацепции / Под ред. В.Н. Прилепской. Бином, 2009.

9. Edelman A, Micks E, Gallo MF, et al. Continuous or extended cycle vs. cyclic use of combined hormonal contraceptives for contraception. Cochrane Database Syst Rev 2014;:CD004695. doi:10.1002/14651858.CD004695.pub3.

10. Nash Zachary, Thwaites Annette, Davies Melanie. Tailored regimens for combined hormonal contraceptives BMJ 2020; 368:m200.

11. FSRH Clinical Guideline: Combined Hormonal Contraception (January 2019, Amended July 2019).

12. Gloviczki P. Handbook of Venous Disorders Guidelines of the American Venous Forum. 3rd ed. / ed. Gloviczki P. Hodder Arnold Publishers, 2009. P. 624.

13. Клинические рекомендации РООМ по профилактике РМЖ, дифференциальной диагностике, лечению, предопухолевых и доброкачественных заболеваний молочных желёз / И. В. Высоцкая, В. П. Летягин, В. Г. Черенков и др. М., 2015. 21 с.

14. Vogt C, Schaefer M. Disparities in knowledge and interest about benefits and risks of combined oral contraceptives. Eur J Contracept Reprod Health Care. 2011;16(3):183–193. doi:10.3109/13625187.2011.561938.

15. Gallo MF, Lopez LM, Grimes DA, Carayon F, Schulz KF, Helmerhorst FM. Combination contraceptives: effects on weight. Cochrane Database of Systematic Reviews 2014, Issue 1. Art. No.: CD003987. DOI: 10.1002/14651858.CD003987.pub5.

16. Nelson AL. Combined oral contraceptives. In: Hatcher RA, Trussell J, Nelson AL, Cates W, Stewart FH, Kowal D, et al.editor(s). Contraceptive Technology. 19th Edition. New York: Ardent Media, Inc., 2007:193–270.

17. Ingela Lindh, Agneta Andersson Ellström, Ian Milsom. The long-term influence of combined oral contraceptives on body weight, Human Reproduction, 2011, pp. 1917–1924, 26/7, DOI: 10.1093/humrep/der094.

18. The European Agency for the Evaluation of Medicinal Products Post-authorisation Evaluation of Medicines for Human use London, 28 September 2001 Doc.

19. Dinger J.C., et al. The safety of a drospirenonecontaining oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142 475 women-years of observation // Contraception 2007; 75 (5): 344-54.

20. Benefits of combined hormonal contraceptives (CHCs) continue to outweigh risks. Product information updated to help women make informed decisions about their choice of contraception // European Medicines Agency. – 2014. – 4 р.